Literature DB >> 15780845

A putative animal model of the "prodromal" state of schizophrenia.

Catherine C Tenn1, Paul J Fletcher, Shitij Kapur.   

Abstract

BACKGROUND: There is growing interest in detecting and treating schizophrenia during the "prodrome," before the symptoms are fully manifested. The objective of this study was to develop a putative model of the prodrome and study the effects of medications on it.
METHODS: Rats were treated with different regimens of amphetamine to produce full sensitization (full syndrome) and partial sensitization (to model the prodromal state) and were then treated with typical and atypical antipsychotics and a D1 antagonist to mimic early intervention. After several weeks of withdrawal, locomotor activity in response to amphetamine and behavioral deficits (prepulse inhibition [PPI] and latent inhibition [LI]) were examined.
RESULTS: Animals that received the full sensitization showed significant increase in locomotor activity and a disruption in both PPI and LI. Animals treated with a partial regimen showed only a muted phenotype. The animals that received "early intervention" did not show progression from the prodromal to the full-blown phenotype.
CONCLUSIONS: The partial regimen of amphetamine injections provided a modified phenotype that could be regarded as a representative of the "prodromal" state. Early intervention, instituted once the prodromal state was already developed, prevented further progression into the full phenotype analogous to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780845     DOI: 10.1016/j.biopsych.2004.12.013

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

1.  Fewer classes of drugs for more and more psychiatric disorders.

Authors:  L Trevor Young
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

2.  Neurocognitive deficits in the (putative) prodrome and first episode of psychosis.

Authors:  A D Eastvold; R K Heaton; K S Cadenhead
Journal:  Schizophr Res       Date:  2007-04-30       Impact factor: 4.939

Review 3.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

4.  Withdrawal from repeated amphetamine administration leads to disruption of prepulse inhibition but not to disruption of latent inhibition.

Authors:  D Peleg-Raibstein; E Sydekum; H Russig; J Feldon
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

5.  Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.

Authors:  Adi Malkoff; Abraham Weizman; Illana Gozes; Moshe Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

6.  PPI deficit induced by amphetamine is attenuated by the histamine H1 antagonist pyrilamine, but is exacerbated by the serotonin 5-HT2 antagonist ketanserin.

Authors:  José A Larrauri; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2010-09-02       Impact factor: 4.530

7.  The effects of adolescent methylphenidate self-administration on responding for a conditioned reward, amphetamine-induced locomotor activity, and neuronal activation.

Authors:  Christie L Burton; José N Nobrega; Paul J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2009-12-18       Impact factor: 4.530

Review 8.  Treatment implications of the schizophrenia prodrome.

Authors:  Tejal Kaur; Kristin S Cadenhead
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 9.  Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions.

Authors:  Jim van Os; Bart Pf Rutten; Richie Poulton
Journal:  Schizophr Bull       Date:  2008-09-12       Impact factor: 9.306

10.  Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Authors:  Urs Meyer; Erica Spoerri; Benjamin K Yee; Markus J Schwarz; Joram Feldon
Journal:  Schizophr Bull       Date:  2008-10-08       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.